FDA Public Workshop: CV Toxicity Assessment in Oncology Trials
The U.S. Food and Drug Administration (FDA) is hosting a public Cardio-Oncology workshop on Sept. 22 from 8:00 a.m. – 4:30 p.m. ET. Co-chaired by Laleh Amiri-Kordestani, MD, and Ana Barac, MD, FACC, chair of ACC’s Cardio-Oncology Member Section, this workshop will provide a forum for discussion of cardiovascular toxicity assessment within oncology clinical trials. There is a growing need for better nonclinical testing platforms, imaging and serum biomarkers and trial designs in order to screen, monitor and prevent these toxicities. The goals of this public workshop are to discuss in vitro and in vivo nonclinical models to assess cardiovascular toxicity, best practices for identifying cardiovascular safety signals within oncology clinical trials, the role of imaging and biomarkers to predict and monitor cardiovascular toxicities, and more. For more information and a draft agenda, click here. Register today.